{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-049236","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.620834+00:00","generated_at":"2026-05-17T00:23:35.891745+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn Q3 net loss narrows to $15.8M; CFO Humer resigns; cash runway into 2028","bullets":["CFO Kristian Humer resigns effective Nov 14, 2025 to pursue other opportunity; no disagreement with company.","Q3 2025 net loss $15.8M vs $19.1M YoY; collaboration revenue $8.2M (vs $7.8M); R&D expenses $20.0M.","Cash, equivalents, and marketable securities $180.3M as of Sept 30, 2025; provides cash runway into 2028.","FHD-909 (SMARCA2 inhibitor) Phase 1 trial in SMARCA4-mutated NSCLC enrolling well; combination data with pembrolizumab and KRAS inhibitors.","Selective CBP degrader IND-ready in 2026; EP300 degrader IND-enabling studies in 2026; ARID1B degrader advancing to in vivo POC in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-049236","json":"https://secwatch.observer/filing/0001628280-25-049236.json","markdown":"https://secwatch.observer/filing/0001628280-25-049236.md","text":"https://secwatch.observer/filing/0001628280-25-049236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025049236/0001628280-25-049236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025049236/fhtx-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:23:35.891745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}